Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial.
Hong-Yan WenJia WangSheng-Xiao ZhangJing LuoXiang-Cong ZhaoChen ZhangCai-Hong WangFang-Yuan HuXiao-Juan ZhengTing ChengHong-Qing NiuGuang-Ying LiuWen-Xian YangNa-Na YuJin-Li RuQi-Xiang ChenXue-Chun LuPei-Feng HeChong GaoXiao-Feng LiPublished in: Journal of immunology research (2019)
Low-dose sirolimus immunoregulatory therapy selectively upregulated Tregs and partly replaced the usage of immunosuppressants to control disease activity without overtreatment and evaluable side effect. Further study is required using a large sample of RA patients treated with sirolimus for a longer period. This trial is registered at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/showproj.aspx?proj=17245).
Keyphrases
- disease activity
- open label
- rheumatoid arthritis
- low dose
- phase iii
- phase ii
- clinical trial
- double blind
- systemic lupus erythematosus
- study protocol
- ankylosing spondylitis
- rheumatoid arthritis patients
- placebo controlled
- high dose
- phase ii study
- juvenile idiopathic arthritis
- interstitial lung disease
- randomized controlled trial
- lymph node metastasis
- squamous cell carcinoma
- stem cells